The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infection

Obeldesivir (ODV; GS-5245) is an orally administered ester prodrug of the parent nucleoside GS-441524 that has broad spectrum antiviral activity inhibiting viral RNA-dependent RNA polymerases. We recently showed that ODV completely protects cynomolgus macaques against lethal infection with Sudan virus when given 24 hours after parenteral exposure. Here, we report that once daily oral ODV treatment of cynomolgus and rhesus macaques for 10 days confers 80 and 100% protection, respectively, against lethal Ebola virus infection when treatment is initiated 24 hours after mucosal (conjunctival) exposure. ODV treatment delayed viral replication to abate excessive inflammation and promote adaptive immunity. For outbreak response, oral antivirals might present substantial advantages over now approved intravenous drugs, such as easy supply, storage, distribution, and administration. Furthermore, these results support the potential of ODV as an oral postexposure prophylaxis with broad spectrum activity across filoviruses.

Authors

Institutions

Publication Details

Journal
Science Advances
Published
2025-03-14
DOI
https://doi.org/10.1126/sciadv.adw0659
Citations
8
Primary Topic
Viral Infections and Outbreaks Research
Type
article
Field-Weighted Citation Impact
11.17
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infection

Mack B. Harrison, Krystle N. Agans, Natalie S. Dobias, Darius Babusis et al.
8 citations
Science Advances
Viral Infections and Outbreaks Research
11.17
article

The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infection

Mack B. Harrison, Krystle N. Agans, Natalie S. Dobias, Darius Babusis, Roy Bannister, Tomáš Cihlář, Abhishek N. Prasad, Courtney Woolsey, Robert W. Cross, Viktoriya Borisevich, Karla A. Fenton, Thomas W. Geisbert, Meghan S. Vermillion, Anh-Quan Nguyen, Daniel J. Deer, Victor C. Chu, Jasmine Martinez
article en
8 citations

Abstract

Obeldesivir (ODV; GS-5245) is an orally administered ester prodrug of the parent nucleoside GS-441524 that has broad spectrum antiviral activity inhibiting viral RNA-dependent RNA polymerases. We recently showed that ODV completely protects cynomolgus macaques against lethal infection with Sudan virus when given 24 hours after parenteral exposure. Here, we report that once daily oral ODV treatment of cynomolgus and rhesus macaques for 10 days confers 80 and 100% protection, respectively, against lethal Ebola virus infection when treatment is initiated 24 hours after mucosal (conjunctival) exposure. ODV treatment delayed viral replication to abate excessive inflammation and promote adaptive immunity. For outbreak response, oral antivirals might present substantial advantages over now approved intravenous drugs, such as easy supply, storage, distribution, and administration. Furthermore, these results support the potential of ODV as an oral postexposure prophylaxis with broad spectrum activity across filoviruses.

Science AdvancesVol. 11(11)
Gilead Sciences (United States) (US), The University of Texas Medical Branch at Galveston (US)
Good health and well-being
Openalex Percentile: Top 1%
Viral Infections and Outbreaks Research
11.17
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.